Ketorolac vs. Steroid in the Prevention of CME

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate if the incidence of sub clinical CME can be significantly reduced by use of peri-operative Acular LS plus Pred Forte when compared with Pred Forte alone in normal cataract patients.

• Phase: Phase 4

Details

• Lead Sponsor: Innovative Medical
• Treatments: Ketorolac; Ketorolac Tromethamine; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• · Male or female > 18 years of age scheduled to undergo cataract surgery with surgeon expectation of 20/20 BCVA postoperatively

• Must be in good general health. Patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (ie diabetics with normal retinal exams)

• Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

• · Known contraindication to any study medication or any of their components

• Uncontrolled systemic disease

• Required use of ocular medications other than the study medications during the study

• Abnormal pre-operative OCTs if obtainable

• Diabetic patients with a history of macular edema or diabetic retinopathy

• AMD patients with less than a 20/20 surgical outcome expectation, epi-retinal membranes, retinal vein occlusion, or any pre-existing macular disease